Skip to content

Released Mar 6, 2025, after the close

10-K filed Mar 6, 2025, 65 days after period end · 0001628280-25-010933

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$2.86Mderived−50.5% vs Q4 2023−63.4% vs Q3 2024
Net Income-$19.50MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$24,005,000N/M
Operating Cash Flowderived-$24,519,000N/M
Free Cash Flowderived-$24,998,000N/M
Margins · derived
Operating margin-840.5%−399.2 pt vs Q4 2023
Net margin-682.9%−265.0 pt vs Q4 2023

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$2.86M$5.77M$4.18M$713.00K
Net Income-$19.50M-$24.11M-$28.89M-$29.14M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR